Alzheimer's Disease

Alzheimer's Disease

Memory loss is a concern of many people, particularly as they age. Memory loss may be due to depression, stress, medical conditions, or a sign of impending dementia such as Alzheimer’s disease. Lifestyle changes can have a great effect on those with modifiable risk factors. These include hearing loss, hypertension, obesity, smoking, depression, physical inactivity, social isolation, diabetes and sleep disorders. Proper diet can also have a positive effect on retaining memory. We at NervePro teach you of these measures. In addition, identifying the earliest clinical and biological changes to intervene with medication is important. Clinical trials should be considered due to the modest benefit available from current medications.

Dementia is a collective term used to describe a condition when in addition to mild short term memory loss, sufficient difficulties have developed to interfere with daily activities such as driving safely, paying bills, plan and prepare a meal, making appointments and being able to organize the household. We will evaluate those with difficulty to determine which type of dementia one may have. Alzheimer’s disease is the most common cause of dementia. In this condition, deposits of Amyloid and tau protein disrupt neuronal pathways and cause brain cell loss. This buildup can occur for over 15 years prior to dementia being diagnosed and can be detected on an amyloid PET scan.

Present treatments for Alzheimer’s disease include acetylcholinesterase blockers which boost the level of the main memory neurotransmitter (donepezil, Excelon, galantamine), and memantine (Namenda) which works through the glutamine pathways. At NervePro, we are participating in a clinical trial for mild cognitive impairment and early to Alzheimer’s dementia. This study will begin in late June 2019 and last for one to two years, each person involved will receive an oral medication for six months while memory and cognition assessments are made. One must be between 55 and 85 years of age, have mild Alzheimer’s, and are able to be taking donepezil, but not memantine while participating in the study. No imaging tests are needed to be involved.

Another study testing a drug to reduce amyloid buildup in the brain is underway but as of January 2019 has stopped new enrollment. Those results should be available in early 2021. Amyloid buildup can begin 10 to 15 years prior to a diagnosis of Alzheimer’s disease, earliest treatment is hoped to prevent this occurrence.

Make a Research Appointment
Phone: 949.753.1570